WuXi AppTec

Dr. Jie Jack Li joins Shanghai ChemPartner as a Vice President of Discovery Chemistry

Retrieved on: 
星期二, 十二月 17, 2019
Natural sciences, Life sciences, Articles, Medicinal chemistry, Cheminformatics, Chemist, Biopharmaceutical, Drug discovery, Process chemistry, Pharmacology, WuXi AppTec

SHANGHAI, Dec. 17, 2019 /PRNewswire/ -- Shanghai ChemPartner announced the appointment of Jie Jack Li, Ph.D. as a Vice President of Discovery Chemistry at the Company headquarters in Shanghai, China.

Key Points: 
  • SHANGHAI, Dec. 17, 2019 /PRNewswire/ -- Shanghai ChemPartner announced the appointment of Jie Jack Li, Ph.D. as a Vice President of Discovery Chemistry at the Company headquarters in Shanghai, China.
  • Dr. Li is an established chemist with over 20 years of experience in both medicinal chemistry and process chemistry.
  • ChemPartner excels at medicinal chemistry design, custom synthesis and library synthesis as well as peptide, nucleoside and natural product chemistry.
  • Shanghai ChemPartner , which includes ChemPartner, Jiangsu ChemPartner, ChemPartner Biologics, and China Gateway Pharmaceutical Development, offers a broad range of drug discovery and development capabilities including biologics discovery, chemistry and medicinal chemistry, biology and pharmacology, DMPK and exploratory toxicology, and small and large molecule CMC.

Dr. Jie Jack Li joins Shanghai ChemPartner as a Vice President of Discovery Chemistry

Retrieved on: 
星期二, 十二月 17, 2019
Natural sciences, Life sciences, Articles, Medicinal chemistry, Cheminformatics, Chemist, Biopharmaceutical, Drug discovery, Process chemistry, Pharmacology, WuXi AppTec

SHANGHAI, Dec. 17, 2019 /PRNewswire/ -- Shanghai ChemPartner announced the appointment of Jie Jack Li, Ph.D. as a Vice President of Discovery Chemistry at the Company headquarters in Shanghai, China.

Key Points: 
  • SHANGHAI, Dec. 17, 2019 /PRNewswire/ -- Shanghai ChemPartner announced the appointment of Jie Jack Li, Ph.D. as a Vice President of Discovery Chemistry at the Company headquarters in Shanghai, China.
  • Dr. Li is an established chemist with over 20 years of experience in both medicinal chemistry and process chemistry.
  • ChemPartner excels at medicinal chemistry design, custom synthesis and library synthesis as well as peptide, nucleoside and natural product chemistry.
  • Shanghai ChemPartner , which includes ChemPartner, Jiangsu ChemPartner, ChemPartner Biologics, and China Gateway Pharmaceutical Development, offers a broad range of drug discovery and development capabilities including biologics discovery, chemistry and medicinal chemistry, biology and pharmacology, DMPK and exploratory toxicology, and small and large molecule CMC.

Global Pharmaceutical Analytical Testing Services Market Procurement Intelligence Report 2019 - ResearchAndMarkets.com

Retrieved on: 
星期一, 十二月 9, 2019
Pharmaceutical, Science, Health, Research, Articles, Business, Contract research organizations, Eurofins Scientific, WuXi AppTec, Procurement, Economy, Quality assurance, Pharmaceuticals policy

The "Global Pharmaceutical Analytical Testing Services Market - Procurement Intelligence Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Pharmaceutical Analytical Testing Services Market - Procurement Intelligence Report" report has been added to ResearchAndMarkets.com's offering.
  • The report recognizes the following companies as the key suppliers in the market - Eurofins GSC Lux Sarl, SGS SA, Charles River Laboratories International Inc, WuXi AppTec Inc, Intertek Group Plc, West Pharmaceutical Services Inc.
  • According to the report, one of the key growth contributors for the global pharmaceutical analytical testing services market is the growing trend of R&D outsourcing by pharmaceutical companies.
  • Further, the report states that one of the key category management strategies for the buyers in the global pharmaceutical analytical testing services market is to engage with suppliers who adopt strategic procurement for lab equipment.

WuXi Vaccines to Build a $240 Million Manufacturing Facility in Ireland

Retrieved on: 
星期五, 十一月 22, 2019
Life sciences, Articles, Biotechnology, Pharmaceutical industry, Contract manufacturing organization, Biopharmaceutical, Vaccine, WuXi AppTec

DUNDALK, Ireland, Nov. 22, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development, and manufacturing, announced that its subsidiary WuXi Vaccines, engaged in human vaccine Contract Development and Manufacturing Organization (CDMO) business,is to invest 240 million USD and build a new vaccine manufacturing facility in Ireland.

Key Points: 
  • DUNDALK, Ireland, Nov. 22, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development, and manufacturing, announced that its subsidiary WuXi Vaccines, engaged in human vaccine Contract Development and Manufacturing Organization (CDMO) business,is to invest 240 million USD and build a new vaccine manufacturing facility in Ireland.
  • The new vaccine manufacturing facility, subject to planning approval, will be located within the WuXi Biologics Campus adjacent to the "Factory of the Future" biologics drug substance manufacturing facility which is scheduled for commercial manufacturing in 2021.
  • As the first vaccines contract manufacturing facility in Ireland, this planned second project will considerably strengthen our life sciences ecosystem and reinforce Ireland's strong manufacturing capabilities."
  • Dr. Chris Chen, CEO of WuXi Biologics and Chairman of WuXi Vaccines, commented, "We're excited to dedicate our first vaccine manufacturing facility in Ireland to enable a large global pharma in the field of vaccines.

WuXi Vaccines to Build a $240 Million Manufacturing Facility in Ireland

Retrieved on: 
星期五, 十一月 22, 2019
Life sciences, Articles, Biotechnology, Pharmaceutical industry, Contract manufacturing organization, Biopharmaceutical, Vaccine, WuXi AppTec

DUNDALK, Ireland, Nov. 22, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development, and manufacturing, announced that its subsidiary WuXi Vaccines, engaged in human vaccine Contract Development and Manufacturing Organization (CDMO) business,is to invest 240 million USD and build a new vaccine manufacturing facility in Ireland.

Key Points: 
  • DUNDALK, Ireland, Nov. 22, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development, and manufacturing, announced that its subsidiary WuXi Vaccines, engaged in human vaccine Contract Development and Manufacturing Organization (CDMO) business,is to invest 240 million USD and build a new vaccine manufacturing facility in Ireland.
  • The new vaccine manufacturing facility, subject to planning approval, will be located within the WuXi Biologics Campus adjacent to the "Factory of the Future" biologics drug substance manufacturing facility which is scheduled for commercial manufacturing in 2021.
  • As the first vaccines contract manufacturing facility in Ireland, this planned second project will considerably strengthen our life sciences ecosystem and reinforce Ireland's strong manufacturing capabilities."
  • Dr. Chris Chen, CEO of WuXi Biologics and Chairman of WuXi Vaccines, commented, "We're excited to dedicate our first vaccine manufacturing facility in Ireland to enable a large global pharma in the field of vaccines.

WuXi AppTec Receives 2019 Global Integrated Drug Development Competitive Strategy Innovation & Leadership Award from Frost & Sullivan

Retrieved on: 
星期五, 十一月 15, 2019
WuXi AppTec, AppTec, Wuxi, Life sciences, Industries, Companies

SHANGHAI, Nov. 14, 2019 /PRNewswire/ -- WuXi AppTec, a leading global provider of R&D and manufacturing services enabling companies in the pharmaceutical, biotechnology and medical device industries, today announced that it received the 2019 Global Integrated Drug Development Competitive Strategy Innovation & Leadership Award from Frost & Sullivan, a global business research and consulting firm.

Key Points: 
  • SHANGHAI, Nov. 14, 2019 /PRNewswire/ -- WuXi AppTec, a leading global provider of R&D and manufacturing services enabling companies in the pharmaceutical, biotechnology and medical device industries, today announced that it received the 2019 Global Integrated Drug Development Competitive Strategy Innovation & Leadership Award from Frost & Sullivan, a global business research and consulting firm.
  • The Frost & Sullivan Best Practices Award series honors companies that have pushed the boundaries of excellence in the areas of leadership, technological innovation, customer service, and business development.
  • Frost & Sullivan recognized WuXi AppTec as a reliable and reputable participant in the global healthcare industry, providing cutting-edge drug discovery and development solutions alongside data management and analytics services.
  • "Thanks Frost & Sullivan for recognizing WuXi's global platform," said Dr. Ge Li, chairman and CEO of WuXi AppTec.

The global pharmaceutical contract development and manufacturing market is projected to grow at a CAGR of 7.1%

Retrieved on: 
星期三, 十一月 13, 2019
Health, Articles, Pharmaceutical industry, Pharmacology, Pharmacy, CNX Nifty, Pharmaceutical industry in China, WuXi AppTec

On the basis of service, the pharmaceutical contract development and manufacturing market is segmented into pharmaceutical manufacturing, biologics manufacturing, and drug development services.The biologics manufacturing segment is projected to witness the highest growth in the pharmaceutical contract development and manufacturing market during the forecast period.

Key Points: 
  • On the basis of service, the pharmaceutical contract development and manufacturing market is segmented into pharmaceutical manufacturing, biologics manufacturing, and drug development services.The biologics manufacturing segment is projected to witness the highest growth in the pharmaceutical contract development and manufacturing market during the forecast period.
  • The big pharma end-user segment holds the largest share of the pharmaceutical contract development and manufacturing market.
  • The Asia Pacific is likely to be the fastest-growing market for players operating in the pharmaceutical contract development and manufacturing market.
  • Although Europe accounted for the largest share of the global pharmaceutical contract development and manufacturing market in 2018, the Asia Pacific is expected to witness the highest CAGR during the forecast period.

Dr. Ge Li Awarded "CEO of the Year" at CPhI Worldwide 2019

Retrieved on: 
星期一, 十一月 11, 2019
Companies, Industries, WuXi AppTec, Articles, General Electric, Pharma, Wuxi, AppTec, Credibility

The 2019 CPhI Pharma Awards recognize the innovation and dedication of companies and individuals who are driving the pharmaceutical industry forward.

Key Points: 
  • The 2019 CPhI Pharma Awards recognize the innovation and dedication of companies and individuals who are driving the pharmaceutical industry forward.
  • Its Judging Panel is comprised of independent, senior industry experts from around the world, each chosen for their knowledge, objectivity and credibility.
  • Dr. Ge Li was chosen for his significant contribution to the global biopharma R&D industry.
  • "I'm honored by this award and its recognition of WuXi's global platform," said Dr. Ge Li, Chairman and CEO of WuXi AppTec.

Vineti and WuXi AppTec Advanced Therapies Collaborate to Simplify Manufacturing Supply Chain for Advanced Therapies

Retrieved on: 
星期三, 十一月 6, 2019
Articles, WuXi AppTec, Systems engineering, Logistics, Business, Life sciences

We are excited to establish a collaboration with WuXi AppTec Advanced Therapies to enable developers of innovative and personalized advanced therapies manufacturing at WuXi AppTecs Advanced Therapies facilities to enjoy the benefits of our Personalized Therapy Management Platform (PTM), providing logistics, scheduling, distribution, tracking, Chain of Identity, Chain of Custody, and Chain of Condition in real time, said Amy DuRoss, CEO and Co-Founder of Vineti.

Key Points: 
  • We are excited to establish a collaboration with WuXi AppTec Advanced Therapies to enable developers of innovative and personalized advanced therapies manufacturing at WuXi AppTecs Advanced Therapies facilities to enjoy the benefits of our Personalized Therapy Management Platform (PTM), providing logistics, scheduling, distribution, tracking, Chain of Identity, Chain of Custody, and Chain of Condition in real time, said Amy DuRoss, CEO and Co-Founder of Vineti.
  • We are pleased to be part of Vineti's partnership program to support both customers that seek to promote streamlining personalized therapies from specimen connections to manufacturing, said Felix Hsu, Senior Vice President and Global Head of WuXi AppTec Advanced Therapies.
  • With our leading integrated manufacturing and testing services, we believe we can bring even more speed, reliability and security to an already complex manufacturing and supply chain.
  • Now a fully independent company, Vineti offers a digital platform of record to integrate logistics, manufacturing and clinical data for personalized therapies.

WuXi AppTec Receives Investment Grade Corporate Ratings from Three Global Rating Agencies

Retrieved on: 
星期三, 十一月 6, 2019
Finance, Money, Economy, Credit rating agencies, WuXi AppTec, Credit rating, AppTec, Standard & Poor's, Bond credit rating, Moody's Investors Service, Fitch Ratings

SHANGHAI, Nov. 6, 2019 /PRNewswire/ -- WuXi AppTec announced today that it has received investment grade corporate credit ratings from three global rating agencies: Moody's (Baa3), S&P Global Ratings (BBB-), and Fitch Ratings (BBB-); all three agencies maintain a stable outlook on WuXi AppTec.

Key Points: 
  • SHANGHAI, Nov. 6, 2019 /PRNewswire/ -- WuXi AppTec announced today that it has received investment grade corporate credit ratings from three global rating agencies: Moody's (Baa3), S&P Global Ratings (BBB-), and Fitch Ratings (BBB-); all three agencies maintain a stable outlook on WuXi AppTec.
  • These ratings reflect WuXi AppTec's leading market position as an integrated end-to-end R&D service platform with strong growth prospects, healthy cash flow and balance sheet, modest leverage and ample liquidity.
  • Third-party recognition of WuXi AppTec's financial stability enables the Company to also fund future growth with debt.
  • As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve the productivity of advancing healthcare products through cost-effective and efficient solutions.